Publikationen, an denen er mitarbeitet Miguel Ángel González-Gay Mantecón (19)

2024

  1. Association of Serum Malondialdehyde Levels with Lipid Profile and Liver Function in Patients with Inflammatory Bowel Disease

    Antioxidants, Vol. 13, Núm. 10

  2. Malondialdehyde Serum Levels in a Full Characterized Series of 430 Rheumatoid Arthritis Patients

    Journal of Clinical Medicine, Vol. 13, Núm. 3

  3. Mean Platelet Volume Is Related to Cumulative Disease Damage in Patients with Systemic Lupus Erythematosus

    Life, Vol. 14, Núm. 4

  4. Red blood cell distribution width as a surrogate biomarker of damage and disease activity in patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 42, Núm. 9, pp. 1773-1780

2023

  1. Alpha-Klotho protein in systemic lupus erythematosus

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 41-47

  2. Blood Composite Scores in Patients with Systemic Lupus Erythematosus

    Biomedicines, Vol. 11, Núm. 10

  3. Disease activity in patients with rheumatoid arthritis increases serum levels of apolipoprotein C-III

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 67-73

  4. Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction

    Antioxidants, Vol. 12, Núm. 9

  5. Mean Platelet Volume in a Series of 315 Patients with Rheumatoid Arthritis: Relationship with Disease Characteristics, including Subclinical Atherosclerosis and Cardiovascular Comorbidity

    Diagnostics, Vol. 13, Núm. 20

  6. Red Cell Distribution Width Association with Subclinical Cardiovascular Disease in Patients with Rheumatoid Arthritis

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  7. Relationship between Disease Characteristics and Circulating Interleukin 6 in a Well-Characterized Cohort of Patients with Systemic Lupus Erythematosus

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  8. Relationship between Malondialdehyde Serum Levels and Disease Features in a Full Characterized Series of 284 Patients with Systemic Lupus Erythematosus

    Antioxidants, Vol. 12, Núm. 8

  9. Relationship of Blood Inflammatory Composite Markers with Cardiovascular Risk Factors and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

    Life, Vol. 13, Núm. 7

  10. Relationship of Fibroblast Growth Factor 23 Serum Levels with Disease Characteristics in Systemic Lupus Erythematosus Patients

    Biomolecules, Vol. 13, Núm. 8

  11. Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease

    International journal of molecular sciences, Vol. 24, Núm. 6

  12. Serum Levels of Transforming Growth Factor Beta 1 in Systemic Lupus Erythematosus Patients

    Biomolecules, Vol. 13, Núm. 1

  13. Transforming growth factor beta 1 is associated with subclinical carotid atherosclerosis in patients with systemic lupus erythematosus

    Arthritis Research and Therapy, Vol. 25, Núm. 1

2022

  1. Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients

    Biomolecules, Vol. 12, Núm. 12

2021

  1. Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus

    Clinical and experimental rheumatology